BioCentury
ARTICLE | Clinical News

Galactoarabino-rhamnogalacturonate: Phase IIa started

October 5, 2015 7:00 AM UTC

Galectin began an open-label, U.S. Phase IIa trial to evaluate 8 mg/kg IV GR-MD-02 every 2 weeks for 7 infusions in 10 patients with >=10% of their skin affected and a PASI score of >=12 points. ...